Anuh Pharma Ltd Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →The company expects approximately 30% growth in top line and bottom line for FY22, targeting revenue between Rs. 480 to 500 crores.
- →Current order book as of 1st July 2021 is Rs. 90 crores, indicating good demand.
- →Q2, Q3, and Q4 sales growth is expected to be similar, driven by conventional products Erythromycin and Pyrazinamide.
- →New products like Gliclazide are contributing and expected to continue providing higher gross margins.
- →Capacity utilization stands at 71%, with plans to expand manufacturing capacity from 1,200 to 1,500 metric tons by March 2022, supporting volume growth.
- →The company is resolving raw material procurement constraints to sustain and improve production and sales.
- →Regulated market sales contribution is expected to increase, with roughly 10% of the top line potentially coming from the USA by 2025.
- →New commercial projects with product backward integration (e.g., Azithromycin) nearing completion, expected to add revenue.
See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- →The company currently has no long-term debt and is essentially debt-free except for some pre-shipment facility at low interest (3% to 3.1%).
- →There is no mention of any current or future fundraising plans through equity or debt in the transcript.
- →The company is focusing on internal accruals for funding, including CAPEX of around Rs. 4 crores for capacity expansion.
- →No plans to associate with any Investor Relations (IR) firm for fundraising are indicated.
- →Overall, the company appears financially stable with no immediate plan for raising funds via debt or equity.
See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- →The company plans to invest an additional ₹4 crores in CAPEX during the current financial year (2021-2022).
- →This investment aims to increase manufacturing capacity from 1,200 metric tons to 1,500 metric tons by 31st March 2022.
- →The expansion involves adding a few equipment and machinery to the existing setup; most infrastructure is ready.
- →The company is actively exploring inorganic expansion opportunities but is waiting for the right candidate or proposal.
- →They welcome acquisition proposals monthly and will proceed when a suitable target is identified.
- →The focus is also on backward integration in production, such as making Azithromycin from earlier stages, to reduce dependence on Chinese imports and improve margins.
Track Anuh Pharma Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →Anuh Pharma expects around 30% growth in both top line and bottom line for FY22, targeting revenues between ₹480 to ₹500 crores.
- →EBITDA margins are projected to be between 13% to 15%.
- →Profit before tax margins are expected in the range of 8% to 10%, improving with increasing sales in regulated markets.
- →Order book as of July 1, 2021, stands at ₹90 crores, indicating strong demand and visibility for growth.
- →New products like Gliclazide, Ambroxol, Azithromycin, Sulfadoxine contribute to higher margins and sales.
- →Resolution of raw material procurement issues, especially local sourcing replacing Chinese imports, is expected to support margin recovery.
- →The company foresees steady capacity utilization improvements with planned capex increasing manufacturing capacity from 1,200 to 1,500 metric tons by March 2022.
- →By 2025, expects at least 10% of revenues from the US regulated market, supporting higher realizations and profits.
Order book
Yes- →The order book position as of 1st July 2021 is ₹90 crore.
- →The company is confident of achieving its top-line and bottom-line targets for the financial year 2022.
- →There is a pending order status as of 1st July 2021, with good sales of products like Gliclazide, Ambroxol, Azithromycin, and Sulfadoxine.
- →Some conventional products like Erythromycin and Pyrazinamide had reduced sales due to COVID-19 but are expected to improve.
- →Raw material procurement issues for one intermediate from China are being resolved with local sourcing expected within 2-3 months to avoid any sales disruptions.
- →Overall, the company expects similar or continued growth in upcoming quarters (Q2, Q3, and Q4) supported by a current strong order book and resolution of raw material constraints.
How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
How does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Ind-Swift Laboratories Ltd (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
- HIKAL (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…